Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [[maximum depth reached]]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/artful-claims-cant-decide-patent-law-court-j-venkatesan-20243/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/artful-claims-cant-decide-patent-law-court-j-venkatesan-20243/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [[maximum depth reached]]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/artful-claims-cant-decide-patent-law-court-j-venkatesan-20243/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/artful-claims-cant-decide-patent-law-court-j-venkatesan-20243/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6823ec7b14bf2-trace').style.display = (document.getElementById('cakeErr6823ec7b14bf2-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6823ec7b14bf2-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6823ec7b14bf2-code').style.display = (document.getElementById('cakeErr6823ec7b14bf2-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6823ec7b14bf2-context').style.display = (document.getElementById('cakeErr6823ec7b14bf2-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6823ec7b14bf2-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6823ec7b14bf2-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20102,
		&#039;title&#039; =&gt; &#039;Artful claims can’t decide patent law: court-J Venkatesan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bench of Justices Aftab Alam and Ranjana Desai said, &amp;quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench noted that in the United States, &amp;lsquo;Gleevec&#039; came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &amp;quot;On its package, the drug was described as &amp;lsquo;Imatinib Mesylate Tablets 100 mg&#039; and it was further stated that &amp;quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&amp;quot; If that be so, and the [appellant&#039;s] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench said, &amp;quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 2 April, 2013, http://www.thehindu.com/todays-paper/tp-national/artful-claims-cant-decide-patent-law-court/article4571673.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;artful-claims-cant-decide-patent-law-court-j-venkatesan-20243&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20243,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20102,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Artful claims can’t decide patent law: court-J Venkatesan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic drugs,novartis,patents,Health,Cancer&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu



The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bench of Justices Aftab Alam and Ranjana Desai said, &amp;quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench noted that in the United States, &amp;lsquo;Gleevec&#039; came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &amp;quot;On its package, the drug was described as &amp;lsquo;Imatinib Mesylate Tablets 100 mg&#039; and it was further stated that &amp;quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&amp;quot; If that be so, and the [appellant&#039;s] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench said, &amp;quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20102,
	&#039;title&#039; =&gt; &#039;Artful claims can’t decide patent law: court-J Venkatesan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bench of Justices Aftab Alam and Ranjana Desai said, &amp;quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench noted that in the United States, &amp;lsquo;Gleevec&#039; came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &amp;quot;On its package, the drug was described as &amp;lsquo;Imatinib Mesylate Tablets 100 mg&#039; and it was further stated that &amp;quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&amp;quot; If that be so, and the [appellant&#039;s] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench said, &amp;quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 2 April, 2013, http://www.thehindu.com/todays-paper/tp-national/artful-claims-cant-decide-patent-law-court/article4571673.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;artful-claims-cant-decide-patent-law-court-j-venkatesan-20243&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20243,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20102
$metaTitle = &#039;LATEST NEWS UPDATES | Artful claims can’t decide patent law: court-J Venkatesan&#039;
$metaKeywords = &#039;generic drugs,novartis,patents,Health,Cancer&#039;
$metaDesc = &#039;
-The Hindu



The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bench of Justices Aftab Alam and Ranjana Desai said, &amp;quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench noted that in the United States, &amp;lsquo;Gleevec&#039; came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &amp;quot;On its package, the drug was described as &amp;lsquo;Imatinib Mesylate Tablets 100 mg&#039; and it was further stated that &amp;quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&amp;quot; If that be so, and the [appellant&#039;s] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench said, &amp;quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/artful-claims-cant-decide-patent-law-court-j-venkatesan-20243.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Artful claims can’t decide patent law: court-J Venkatesan | Im4change.org</title>
    <meta name="description" content="
-The Hindu



The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Artful claims can’t decide patent law: court-J Venkatesan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu</div><p align="justify"><br />The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer drug.</p><p align="justify">A Bench of Justices Aftab Alam and Ranjana Desai said, &quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&quot;</p><p align="justify">The Bench noted that in the United States, &lsquo;Gleevec' came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &quot;On its package, the drug was described as &lsquo;Imatinib Mesylate Tablets 100 mg' and it was further stated that &quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&quot; If that be so, and the [appellant's] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&quot;</p><p align="justify">The Bench said, &quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.</p><p align="justify">It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&quot;</p><p align="justify">&quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&quot;</p><p align="justify">The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6823ec7b14bf2-trace').style.display = (document.getElementById('cakeErr6823ec7b14bf2-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6823ec7b14bf2-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6823ec7b14bf2-code').style.display = (document.getElementById('cakeErr6823ec7b14bf2-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6823ec7b14bf2-context').style.display = (document.getElementById('cakeErr6823ec7b14bf2-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6823ec7b14bf2-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6823ec7b14bf2-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20102,
		&#039;title&#039; =&gt; &#039;Artful claims can’t decide patent law: court-J Venkatesan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bench of Justices Aftab Alam and Ranjana Desai said, &amp;quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench noted that in the United States, &amp;lsquo;Gleevec&#039; came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &amp;quot;On its package, the drug was described as &amp;lsquo;Imatinib Mesylate Tablets 100 mg&#039; and it was further stated that &amp;quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&amp;quot; If that be so, and the [appellant&#039;s] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench said, &amp;quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 2 April, 2013, http://www.thehindu.com/todays-paper/tp-national/artful-claims-cant-decide-patent-law-court/article4571673.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;artful-claims-cant-decide-patent-law-court-j-venkatesan-20243&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20243,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20102,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Artful claims can’t decide patent law: court-J Venkatesan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic drugs,novartis,patents,Health,Cancer&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu



The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bench of Justices Aftab Alam and Ranjana Desai said, &amp;quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench noted that in the United States, &amp;lsquo;Gleevec&#039; came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &amp;quot;On its package, the drug was described as &amp;lsquo;Imatinib Mesylate Tablets 100 mg&#039; and it was further stated that &amp;quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&amp;quot; If that be so, and the [appellant&#039;s] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench said, &amp;quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20102,
	&#039;title&#039; =&gt; &#039;Artful claims can’t decide patent law: court-J Venkatesan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bench of Justices Aftab Alam and Ranjana Desai said, &amp;quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench noted that in the United States, &amp;lsquo;Gleevec&#039; came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &amp;quot;On its package, the drug was described as &amp;lsquo;Imatinib Mesylate Tablets 100 mg&#039; and it was further stated that &amp;quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&amp;quot; If that be so, and the [appellant&#039;s] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench said, &amp;quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 2 April, 2013, http://www.thehindu.com/todays-paper/tp-national/artful-claims-cant-decide-patent-law-court/article4571673.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;artful-claims-cant-decide-patent-law-court-j-venkatesan-20243&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20243,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20102
$metaTitle = &#039;LATEST NEWS UPDATES | Artful claims can’t decide patent law: court-J Venkatesan&#039;
$metaKeywords = &#039;generic drugs,novartis,patents,Health,Cancer&#039;
$metaDesc = &#039;
-The Hindu



The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bench of Justices Aftab Alam and Ranjana Desai said, &amp;quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench noted that in the United States, &amp;lsquo;Gleevec&#039; came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &amp;quot;On its package, the drug was described as &amp;lsquo;Imatinib Mesylate Tablets 100 mg&#039; and it was further stated that &amp;quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&amp;quot; If that be so, and the [appellant&#039;s] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench said, &amp;quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/artful-claims-cant-decide-patent-law-court-j-venkatesan-20243.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Artful claims can’t decide patent law: court-J Venkatesan | Im4change.org</title>
    <meta name="description" content="
-The Hindu



The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Artful claims can’t decide patent law: court-J Venkatesan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu</div><p align="justify"><br />The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer drug.</p><p align="justify">A Bench of Justices Aftab Alam and Ranjana Desai said, &quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&quot;</p><p align="justify">The Bench noted that in the United States, &lsquo;Gleevec' came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &quot;On its package, the drug was described as &lsquo;Imatinib Mesylate Tablets 100 mg' and it was further stated that &quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&quot; If that be so, and the [appellant's] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&quot;</p><p align="justify">The Bench said, &quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.</p><p align="justify">It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&quot;</p><p align="justify">&quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&quot;</p><p align="justify">The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6823ec7b14bf2-trace').style.display = (document.getElementById('cakeErr6823ec7b14bf2-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6823ec7b14bf2-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6823ec7b14bf2-code').style.display = (document.getElementById('cakeErr6823ec7b14bf2-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6823ec7b14bf2-context').style.display = (document.getElementById('cakeErr6823ec7b14bf2-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6823ec7b14bf2-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6823ec7b14bf2-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20102,
		&#039;title&#039; =&gt; &#039;Artful claims can’t decide patent law: court-J Venkatesan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bench of Justices Aftab Alam and Ranjana Desai said, &amp;quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench noted that in the United States, &amp;lsquo;Gleevec&#039; came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &amp;quot;On its package, the drug was described as &amp;lsquo;Imatinib Mesylate Tablets 100 mg&#039; and it was further stated that &amp;quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&amp;quot; If that be so, and the [appellant&#039;s] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench said, &amp;quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 2 April, 2013, http://www.thehindu.com/todays-paper/tp-national/artful-claims-cant-decide-patent-law-court/article4571673.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;artful-claims-cant-decide-patent-law-court-j-venkatesan-20243&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20243,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20102,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Artful claims can’t decide patent law: court-J Venkatesan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic drugs,novartis,patents,Health,Cancer&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu



The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bench of Justices Aftab Alam and Ranjana Desai said, &amp;quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench noted that in the United States, &amp;lsquo;Gleevec&#039; came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &amp;quot;On its package, the drug was described as &amp;lsquo;Imatinib Mesylate Tablets 100 mg&#039; and it was further stated that &amp;quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&amp;quot; If that be so, and the [appellant&#039;s] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench said, &amp;quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20102,
	&#039;title&#039; =&gt; &#039;Artful claims can’t decide patent law: court-J Venkatesan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bench of Justices Aftab Alam and Ranjana Desai said, &amp;quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench noted that in the United States, &amp;lsquo;Gleevec&#039; came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &amp;quot;On its package, the drug was described as &amp;lsquo;Imatinib Mesylate Tablets 100 mg&#039; and it was further stated that &amp;quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&amp;quot; If that be so, and the [appellant&#039;s] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench said, &amp;quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 2 April, 2013, http://www.thehindu.com/todays-paper/tp-national/artful-claims-cant-decide-patent-law-court/article4571673.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;artful-claims-cant-decide-patent-law-court-j-venkatesan-20243&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20243,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20102
$metaTitle = &#039;LATEST NEWS UPDATES | Artful claims can’t decide patent law: court-J Venkatesan&#039;
$metaKeywords = &#039;generic drugs,novartis,patents,Health,Cancer&#039;
$metaDesc = &#039;
-The Hindu



The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis&#039; claim for patent for its cancer drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bench of Justices Aftab Alam and Ranjana Desai said, &amp;quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench noted that in the United States, &amp;lsquo;Gleevec&#039; came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &amp;quot;On its package, the drug was described as &amp;lsquo;Imatinib Mesylate Tablets 100 mg&#039; and it was further stated that &amp;quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&amp;quot; If that be so, and the [appellant&#039;s] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench said, &amp;quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/artful-claims-cant-decide-patent-law-court-j-venkatesan-20243.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Artful claims can’t decide patent law: court-J Venkatesan | Im4change.org</title>
    <meta name="description" content="
-The Hindu



The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Artful claims can’t decide patent law: court-J Venkatesan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu</div><p align="justify"><br />The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer drug.</p><p align="justify">A Bench of Justices Aftab Alam and Ranjana Desai said, &quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&quot;</p><p align="justify">The Bench noted that in the United States, &lsquo;Gleevec' came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &quot;On its package, the drug was described as &lsquo;Imatinib Mesylate Tablets 100 mg' and it was further stated that &quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&quot; If that be so, and the [appellant's] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&quot;</p><p align="justify">The Bench said, &quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.</p><p align="justify">It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&quot;</p><p align="justify">&quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&quot;</p><p align="justify">The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 20102,
		'title' => 'Artful claims can’t decide patent law: court-J Venkatesan',
		'subheading' => '',
		'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
<br />
The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer drug.
</p>
<p align="justify">
A Bench of Justices Aftab Alam and Ranjana Desai said, &quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&quot;
</p>
<p align="justify">
The Bench noted that in the United States, &lsquo;Gleevec' came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &quot;On its package, the drug was described as &lsquo;Imatinib Mesylate Tablets 100 mg' and it was further stated that &quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&quot; If that be so, and the [appellant's] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&quot;
</p>
<p align="justify">
The Bench said, &quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.
</p>
<p align="justify">
It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&quot;
</p>
<p align="justify">
&quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&quot;
</p>
<p align="justify">
The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.
</p>',
		'credit_writer' => 'The Hindu, 2 April, 2013, http://www.thehindu.com/todays-paper/tp-national/artful-claims-cant-decide-patent-law-court/article4571673.ece',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'artful-claims-cant-decide-patent-law-court-j-venkatesan-20243',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 20243,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 20102,
	'metaTitle' => 'LATEST NEWS UPDATES | Artful claims can’t decide patent law: court-J Venkatesan',
	'metaKeywords' => 'generic drugs,novartis,patents,Health,Cancer',
	'metaDesc' => '
-The Hindu



The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer...',
	'disp' => '<div align="justify">-The Hindu</div><p align="justify"><br />The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer drug.</p><p align="justify">A Bench of Justices Aftab Alam and Ranjana Desai said, &quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&quot;</p><p align="justify">The Bench noted that in the United States, &lsquo;Gleevec' came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &quot;On its package, the drug was described as &lsquo;Imatinib Mesylate Tablets 100 mg' and it was further stated that &quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&quot; If that be so, and the [appellant's] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&quot;</p><p align="justify">The Bench said, &quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.</p><p align="justify">It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&quot;</p><p align="justify">&quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&quot;</p><p align="justify">The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 20102,
	'title' => 'Artful claims can’t decide patent law: court-J Venkatesan',
	'subheading' => '',
	'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
<br />
The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer drug.
</p>
<p align="justify">
A Bench of Justices Aftab Alam and Ranjana Desai said, &quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&quot;
</p>
<p align="justify">
The Bench noted that in the United States, &lsquo;Gleevec' came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &quot;On its package, the drug was described as &lsquo;Imatinib Mesylate Tablets 100 mg' and it was further stated that &quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&quot; If that be so, and the [appellant's] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&quot;
</p>
<p align="justify">
The Bench said, &quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.
</p>
<p align="justify">
It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&quot;
</p>
<p align="justify">
&quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&quot;
</p>
<p align="justify">
The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.
</p>',
	'credit_writer' => 'The Hindu, 2 April, 2013, http://www.thehindu.com/todays-paper/tp-national/artful-claims-cant-decide-patent-law-court/article4571673.ece',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'artful-claims-cant-decide-patent-law-court-j-venkatesan-20243',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 20243,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 20102
$metaTitle = 'LATEST NEWS UPDATES | Artful claims can’t decide patent law: court-J Venkatesan'
$metaKeywords = 'generic drugs,novartis,patents,Health,Cancer'
$metaDesc = '
-The Hindu



The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer...'
$disp = '<div align="justify">-The Hindu</div><p align="justify"><br />The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer drug.</p><p align="justify">A Bench of Justices Aftab Alam and Ranjana Desai said, &quot;We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent.&quot;</p><p align="justify">The Bench noted that in the United States, &lsquo;Gleevec' came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. &quot;On its package, the drug was described as &lsquo;Imatinib Mesylate Tablets 100 mg' and it was further stated that &quot;each film coated tablet contains: 100 mg Imatinib (as Mesylate).&quot; If that be so, and the [appellant's] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country.&quot;</p><p align="justify">The Bench said, &quot;Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis.</p><p align="justify">It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent.&quot;</p><p align="justify">&quot;Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India.&quot;</p><p align="justify">The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Artful claims can’t decide patent law: court-J Venkatesan

-The Hindu The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer drug. A Bench of Justices Aftab Alam and Ranjana Desai said, "We certainly do not wish the law of patent... to develop on the lines where there may be a vast gap between the coverage and the disclosure under the patent; where the scope of the patent is determined not on the intrinsic worth of the invention but by the artful drafting of its claims by skilful lawyers; and where patents are traded as a commodity not for production and marketing of the patented products but to search for someone who may be sued for infringement of the patent." The Bench noted that in the United States, ‘Gleevec' came to the market in 2001, and what was marketed then, beyond doubt, was Imatinib Mesylate. "On its package, the drug was described as ‘Imatinib Mesylate Tablets 100 mg' and it was further stated that "each film coated tablet contains: 100 mg Imatinib (as Mesylate)." If that be so, and the [appellant's] claim for patent for the beta crystalline form of Imatinib Mesylate would only appear as an attempt to obtain patent for Imatinib Mesylate, which would otherwise not be permissible in this country." The Bench said, "Since the grant of the Zimmermann patent, the appellant has maintained that Gleevec [Imatinib Mesylate] is part of the Zimmermann patent. It obtained drug approval for Gleevec on that basis. It claimed extension of the term of the Zimmermann patent for the period of regulatory review for Gleevec, and it successfully stopped NATCO Pharma Ltd. from marketing its drug in the U.K. on the basis of the Zimmermann patent." "Not only the appellant but the U.S. Board of Patent Appeals, in its judgment granting patent for the beta crystalline form of Imatinib Mesylate, proceeded on the basis that though the beta crystal form might not have been covered by the Zimmermann patent, the Zimmermann patent had the teaching for the making of Imatinib Mesylate from Imatinib and for its use in a pharmacological compositions for treating tumours or in a method of treating warm-blooded animals suffering from a tumoral disease. We thus find no force in the submission that the development of Imatinib Mesylate from Imatinib is outside the Zimmermann patent and constitutes an invention as understood in the law of patent in India." The Bench dismissed the appeal filed by Novartis and allowed the appeals filed by NATCO Pharma and Cancer Patients Aid Association.